Infective Endocarditis in Injection Drug Users: Unmasking Risks and Finding Pathways to Better Outcomes
"New research spotlights the clinical characteristics and mortality factors associated with infective endocarditis among persons who inject drugs, emphasizing the critical need for integrated addiction treatment and optimized surgical selection."
Infective endocarditis (IE), an infection of the heart's inner lining or valves, has seen a significant shift in patient demographics. Increasingly, it affects individuals who inject drugs (PWID), a group often facing barriers to optimal medical care and specialized addiction services.
A recent study published in JAMA Network Open sheds light on the clinical characteristics and factors influencing mortality in PWID with first-episode IE. This research is crucial because it addresses the discrepancies in understanding and treating IE within this vulnerable population, especially amidst the ongoing opioid crisis.
The study compares clinical characteristics of PWID undergoing surgical versus medical management for IE and identifies key variables associated with survival rates. By examining these factors, the research aims to inform and improve treatment strategies, ultimately reducing mortality and enhancing the quality of care for PWID.
Team-Based Care for Better Outcomes
The American Heart Association says infective endocarditis in people who inject drugs requires a team of specialists. It emphasizes that consultation with addiction-trained clinicians is as important as involvement from traditional members of the endocarditis team. The statement links this collaborative approach to improving outcomes.
From Fatal Disease to Better Diagnosis and Treatment
A 2011 historical review describes infective endocarditis as a fatal disease three generations ago. It credits evolving knowledge with advances in diagnosis, especially echocardiography, and with making cardiac surgery during active infection possible. The review also notes the development of guidelines for antibiotic prophylaxis before interventional procedures. A CDC overview lists developments including updated and modified Duke criteria and molecular diagnosis of causal agents.
What the Research Reveals About Infective Endocarditis in PWID
The JAMA Network Open study, led by Laura Rodger and Michael Silverman, analyzed data from 370 first-episode IE cases, with 202 involving PWID, between April 1, 2007, and March 30, 2016. The research team assessed various factors, including causative organisms, infection sites, cardiac and non-cardiac complications, addiction service referrals, and surgical versus medical management approaches. The primary goal was to pinpoint factors influencing survival among PWID.
- Demographic insights: Most PWID were male (52%), with a median age of 34. A significant majority tested positive for the hepatitis C virus (69.8%).
- Infection Characteristics: Right-sided infections were more common (61.4%), predominantly caused by Staphylococcus aureus (77.2%).
- Treatment approaches: Surgery was performed in 19.3% of patients.
- Mortality rates: The overall mortality rate was 33.7%.
Recent Findings on Valve Involvement and Risk
A systematic review and meta-analysis reports that people who inject drugs had a 1.49-fold higher risk of right-sided than left-sided infective endocarditis (RR 1.49; 95% CI 1.15–1.95; p = 0.008). In a study of patients undergoing valvular surgery for infective endocarditis who abuse opioids, 49 patients—over 65%—reported a history of intravenous heroin use, while 16 (21.3%) were identified as cocaine users. A nationwide analysis found that older age, fungemia, and hemodialysis were independently associated with in-hospital mortality, with odds ratios of 1.018, 2.39, and 3.60, respectively. A 2026 review describes care for drug-use-associated endocarditis as historically involving variable participation from multiple specialties and offers recommendations based on literature review and clinical experience.
Limits of Evidence and Persistent Care Challenges
A study of first-episode infective endocarditis among people who inject drugs found surgery was associated with reduced mortality, but said it could not rule out selection bias from unmeasured factors, such as clinicians’ impressions of relapse risk. Research on medications for opioid use disorder and mortality after hospitalization describes its findings as subject to confounding by indication. Another review notes that tricuspid vegetations are considered a hallmark of injection drug use-associated endocarditis, but their presence on transthoracic echocardiography had not been identified as a recurrence risk factor. A 2022 review describes poor long-term outcomes and high reinfection and readmission rates as challenges in this population.
Outcomes and Differences by Injected Drug Type
A study comparing patients with injection drug use-related and non-injection-drug-use-related infective endocarditis found similar all-cause mortality one year after the sentinel admission, despite the injection drug use group being younger, having fewer medical comorbidities, and having fewer prior cardiac surgeries. In a separate study, 47 of 71 people who injected only opioids (69%) developed right-sided endocarditis; 17 (25%) had left-sided disease and 4 (6%) had bilateral disease. These findings describe different comparisons: one concerns one-year mortality between patient groups, while the other reports valve location among people injecting opioids alone.
The Path Forward: Integrating Addiction Care and Optimizing Treatment Strategies
This study highlights critical considerations for treating infective endocarditis in PWID. The findings support integrating addiction treatment services into the care pathway, as referral to such services was associated with reduced mortality. Future research should focus on refining the criteria for surgical intervention in PWID, ensuring that the most appropriate candidates receive this potentially life-saving treatment. By addressing both the infection and the underlying addiction, healthcare providers can improve outcomes and reduce mortality in this vulnerable population.
Evolving Trends and Uncertain Mortality Patterns
A September 2026 article comparing AHA 2026 and ESC 2023 updates says the AHA documents a continuing rise in infective endocarditis incidence since its 2015 statement. It attributes the trend to converging factors, including an ageing population with more comorbidity, wider use of prosthetic valves and cardiovascular implantable electronic devices, and injection drug use-associated endocarditis. A September 2026 JACC Advances article says substance use is a major driver of infective endocarditis in young U.S. adults, while noting that recent national mortality trends remain unclear. A 2023 review identifies opioid use, including prescription opiates, heroin, and fentanyl, as trends of concern.
Rare Severe Disease and Ongoing Readmission Burden
A January 2026 case report describes a patient with injection drug use, a patent foramen ovale, and recurrent MRSA bacteremia who developed rare, fatal infective endocarditis involving all four heart valves. The report highlights early recognition, surgical consultation, and substance use treatment as important considerations. A 2019 study reports that infective endocarditis in injection drug users was increasing in incidence and associated with decreased mortality during the initial admission. It also found equivalent 30- and 180-day readmission rates and increased risk of readmission for septicemia, endocarditis, and drug abuse.